ESMO ADVANCED COURSE PROGRAMME

EGFR IN LUNG CANCER

Hong Kong SAR
26-27 January 2024

CO-CHAIRS
Tony S. K. Mok, Hong Kong SAR
Solange Peters, Switzerland

SPEAKERS
Lyudmila Bazhenova, United States
Enriqueta Felip, Spain
Rina Hui, Hong Kong SAR
Keith M. Kerr, United Kingdom
Molly S. C. Li, Hong Kong SAR
David Planchard, France
Suresh S. Ramalingam, United States
Daniel S. W. Tan, Singapore
James C.-H. Yang, Taiwan
Pan-Chyr Yang, Taiwan
Yi-Long Wu, China

LEARNING OBJECTIVES

- To understand the role of molecular diagnostic test on tissue and plasma samples for diagnosis, monitoring and TKI resistance in management of epidermal growth factor receptor (EGFR) mutation positive (M+) lung cancer
- To comprehend management of early stage and local advanced EGFR M+ lung cancer
- To gain updated information on optimal first line management and treatment of TKI resistance
- To interrogate the potential use of immunotherapy for patients with EGFR M+ lung cancer

Friday, 26 January 2024

09:00-09:10 Welcome and introduction
Tony S. K. Mok, HKSAR
Solange Peters, CH

09:10-10:25 Session 1 -- Diagnosis and early detection
(Chair: Keith M. Kerr, UK)

20’ Biomarker testing for NSCLC: Why should it be comprehensive and/or reflex?
Keith M. Kerr, UK

20’ The role of liquid biopsy in management of EGFR M+ lung cancer: Initial diagnosis, monitoring and resistance
Molly S. C. Li, HKSAR

20’ Early detection of lung cancer among never smokers
Pan-Chyr Yang, TW

15’ Discussion
10:25-10:55 Coffee break

10:55-11:50 Session 2 — Optimal standard of care
(Chair: Solange Peters, CH)

20’ The art of optimal first line therapy for patients with sensitizing or uncommon EGFR M+ lung cancer
Tony S. K. Mok, HK SAR

20’ Potential combination therapy for EGFR M+ lung cancer
Rina Hui, HK SAR

15’ Discussion

11:50-12:45 Session 3 — EGFR TKI resistance
(Chair: Tony S. K. Mok, HK SAR)

20’ Understanding and overcoming resistance to EGFR TKI: Mechanisms and dynamics
David Planchard, FR

20’ Treatment strategy for management EGFR TKI resistance
Lyudmila Bazhenova, US

15’ Discussion

12:45-13:15 Lunch

13:45-15:00 Session 4 — Early EGFR M+ NSCLC
(Chair: Daniel S. W. Tan, SG)

20’ Adjuvant therapy for resectable EGFR M+ lung cancer
Yi-Long Wu, CN

20’ How to manage stage III EGFR M+ lung cancer
Suresh S. Ramalingam, US

20’ Next generation neo-adjuvant and adjuvant trials in EGFR M+ and other oncogene addicted lung cancer
(excluding IO)
Enriqueta Felip, ES

15’ Discussion

15:00-15:30 Coffee break

15:30-16:50 Session 5 — Facing the uncertainties
(Chair: Suresh S. Ramalingam)

25’ Role of IO in early and advanced stage EGFR M+ lung cancer
Solange Peters, CH

20’ Biology and impact of co-mutations on management of EGFR M+ lung cancer
Daniel S. W. Tan, SG

20’ Novel treatment approaches to EGFR M+ lung cancer
James C.-H. Yang, US

15’ Discussion and closure of the day

19:00 Networking dinner
09:00-12:30  Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)

- 25’ Introduction based on clinical cases presented by speakers
- 30’ Discussion
- 5’ Break

**Workshop 1**

60’ Oligometastasis, oligoprogression and systemic progression: How best to address

Molly S. C. Li, HKSAR
Suresh S. Ramalingam, US

**Workshop 2**

60’ Interrogations for early stage EGFR M+ NSCLC

David Planhard, FR
Rina Hui, HKSAR

**Workshop 3**

60’ Prevention and management of brain and leptomeningeal metastases

Daniel S.W. Tan, SG
James C.-H. Yang, TW

11:00-11:30  **Coffee break**

11:30-12:30  Workshops continuation

12:30-13:00  Synthesis and wrap-up

Tony S. K. Mok, HKSAR
Solange Peters, CH

13:00-14:00  **Lunch**